SEC Form 6-K filed by Fresenius Medical Care AG
$FMS
Misc Health and Biotechnology Services
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | $25.60 | Buy | Berenberg |
| 1/8/2024 | Equal-Weight → Underweight | Morgan Stanley | |
| 11/24/2023 | Reduce → Hold | HSBC Securities | |
| 11/17/2023 | Hold → Buy | Societe Generale | |
| 8/14/2023 | Buy → Neutral | UBS | |
| 8/1/2023 | Neutral | Citigroup | |
| 7/12/2023 | Buy | Goldman | |
| 3/7/2023 | Mkt Perform | Bernstein |
Berenberg initiated coverage of Fresenius Medical with a rating of Buy and set a new price target of $25.60
Morgan Stanley downgraded Fresenius Medical from Equal-Weight to Underweight
HSBC Securities upgraded Fresenius Medical from Reduce to Hold
6-K - Fresenius Medical Care AG (0001333141) (Filer)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)
SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)
SC 13D/A - Fresenius Medical Care AG & Co. KGaA (0001333141) (Subject)
Investors demanded more clarity from German healthcare group Fresenius SE regarding its intentions to relinquish strategic control over dialysis group Fresenius Medical Care AG (NYSE:FMS). The investors’ call for transparency comes in the wake of Fresenius’s recent deconsolidation of Fresenius Medical Care, where the company still retains a 32% stake. Fresenius Medical Care faced significant challenges during the COVID-19 pandemic, including a higher mortality rate among dialysis patients and a shortage of nursing staff. “The volatility at Fresenius Medical Care seems to repeatedly overshadow the recent positive operating developments at Fresenius and is also deterring many potent
Truist Securities analyst David Macdonald maintains Fresenius Medical Care (NYSE:FMS) with a Hold and raises the price target from $21 to $24.
Organic revenue growth of +2% supported by Care Enablement and Care DeliveryUnderlying U.S. dialysis treatment volume growth turns positiveExceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3Both segments further increased operating income1 and operating income margin1Net financial leverage ratio further improved to 2.8xFY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous rangeBAD HOMBURG, Germany, Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The C
A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments.Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different regions.Nearly 75 abstracts presented across a broad range of cutting-edge research, covering topics from the global impact of dialysis to advancements in kidney care technology, sustainability, and health equity.BAD HOMBURG, Germany, Oct. 21, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world'
Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapyThis growth has generated greater adoption from a range of dialysis providers and delivers on the company's commitment to grow access to and use of home dialysis therapyThe newest NxStage® Versi®HD with GuideMe Software home dialysis machine is designed to simplify treatment, increase ease of learning, and improve user experienceWALTHAM, Mass., Sept. 4, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), a global leader in kidney care, has achieved a growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage
Organic revenue growth of +2% supported by Care Enablement and Care DeliveryUnderlying U.S. dialysis treatment volume growth turns positiveExceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3Both segments further increased operating income1 and operating income margin1Net financial leverage ratio further improved to 2.8xFY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous rangeBAD HOMBURG, Germany, Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The C
Organic revenue growth of +2.3% supported by both segments Care Delivery and Care EnablementOperating income1 and operating income margin1 increase driven by Care EnablementAdditional FME25 savings of EUR 57 million achieved and on track to reach the upper end of the full year savings target rangeFurther divestitures closed as execution of portfolio optimization program continuesNet financial debt and net leverage ratio further improvedFY 2024 outlook confirmedBAD HOMBURG, Germany, July 30, 2024 /PRNewswire/ -- "In the second quarter, we further improved our financial performance while executing against our strategic plan and the company transformation. This quarter is another important proo
Today's Annual General Meeting was the first one following the change in legal form completed in November 2023Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an increase of around 6 percent compared to the previous yearNew compensation system for Management Board approvedAmbitious growth targets for 2024 confirmedBAD HOMBURG, Germany, May 16, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024.
Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board roleJörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectorsBAD HOMBURG, Germany, March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.
BAD HOMBURG, Germany, Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located in Germany. Fresenius Medical Care succ
Extraordinary General Meeting approves conversion of Fresenius Medical Care's legal formSeveral advantages including faster and more agile decision-makingMichael Sen elected as Chair of new Supervisory BoardConversion expected to be completed by the end of 2023WALTHAM, Mass., July 14, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting (EGM) today. The Company's shareholders approved all agenda items with large majority, including the conversion of Fresenius Medical Care from the legal form of a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a